Novo Nordisk has officially launched its globally known diabetes and weight-management drug, Ozempic, in India. The once-weekly injectable treatment will be available starting at ₹8,800 for a four-week supply, the company announced on Friday.

Ozempic, which contains the active ingredient semaglutide, is approved in India for adults with uncontrolled type 2 diabetes, and is recommended alongside diet and exercise. The drug is available in 0.25 mg, 0.5 mg, and 1 mg doses, delivered through a pre-filled single-use pen designed for comfortable and painless subcutaneous injections.

The pricing for the three variants is as follows:

0.25 mg (starter dose): ₹8,800

0.5 mg: ₹10,170

1 mg: ₹11,175

Each pen contains four weekly doses.

Vikrant Shrotriya, Managing Director of Novo Nordisk India, s

See Full Page